The influence of proton pump inhibitors and other commonly used medication on the gut microbiota
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Proton pump inhibitors (PPIs), used to treat gastro-esophageal reflux and prevent gastric ulcers, are among the most widely used drugs in the world. The use of PPIs is associated with an increased risk of enteric infections. Since the gut microbiota can, depending on composition, increase or decrease the risk of enteric infections, we investigated the effect of PPI-use on the gut microbiota. We discovered profound differences in the gut microbiota of PPI users: 20% of their bacterial taxa were statistically significantly altered compared with those of non-users. Moreover, we found that it is not only PPIs, but also antibiotics, antidepressants, statins and other commonly used medication were associated with distinct gut microbiota signatures. As a consequence, commonly used medications could affect how the gut microbiota resist enteric infections, promote or ameliorate gut inflammation, or change the host's metabolism. More studies are clearly needed to understand the role of commonly used medication in altering the gut microbiota as well as the subsequent health consequences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human gut microbes associated with obesity
Ley, R. E., Turnbaugh, P. J., Klein, S., & Gordon, J. I. (2006) · Nature · doi:10.1038/4441022a · Cited by 8,785 · cited 1×
“Gut microbiota alterations have large effects on body mass index (BMI), lipid- and cholesterol-levels.(12,33,34) The effects of some medications on the development of obesity have received considerable attention, for example, the effect of antibiotic use during childhood on obesity 35 Use of other drugs is also relate…”
BackgroundCommensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells
Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., et al. (2013) · Nature · doi:10.1038/nature12721 · Cited by 5,549
Vrieze, A., Van Nood, E., Holleman, F., Salojärvi, J., Kootte, R. S., Bartelsman, J. F. W. M., Dallinga–Thie, G. M., Ackermans, M. T., Serlie, M. J., Oozeer, R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.031 · Cited by 2,913
Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota
Atarashi, K., Tanoue, T., Oshima, K., Suda, W., Nagano, Y., Nishikawa, H., Fukuda, S., Saito, T., Narushima, S., Hase, K., et al. (2013) · Nature · doi:10.1038/nature12331 · Cited by 2,872 · cited 1×
“Favorable microbiota can ameliorate gut inflammation through the induction of regulatory Tcells (Tregs), interleukin 10 (IL-10) and the production of the short-chain fatty acid butyrate.(26,27) In contrast, unfavorable microbiota can produce toxins that promote inflammation of the gut epithelium.”
BackgroundPopulation-level analysis of gut microbiome variation
Falony, G., Joossens, M., Vieira-Silva, S., Wang, J., Darzi, Y., Faust, K., Kurilshikov, A., Bonder, M. J., Valles-Colomer, M., Vandeputte, D., et al. (2016) · Science · doi:10.1126/science.aad3503 · Cited by 2,400
Self-citationDisentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota
MetaHIT consortium, Forslund, K., Hildebrand, F., Nielsen, T., Falony, G., Le Chatelier, E., Sunagawa, S., Prifti, E., Vieira-Silva, S., Gudmundsdottir, V., et al. (2015) · Nature · doi:10.1038/nature15766 · Cited by 2,116
Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity
Zhernakova, A., Kurilshikov, A., Bonder, M. J., Tigchelaar, E. F., Schirmer, M., Vatanen, T., Mujagic, Z., Vila, A. V., Falony, G., Vieira-Silva, S., et al. (2016) · Science · doi:10.1126/science.aad3369 · Cited by 1,914 · cited 3×
“1).(9) Consistent with our earlier results, the variance in the gut microbiota that could be explained by PPI use was the largest of all the commonly used drugs.”
BackgroundResultSelf-citationPrecision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile
Buffie, C. G., Bucci, V., Stein, R. R., McKenney, P. T., Ling, L., Gobourne, A., No, D., Liu, H., Kinnebrew, M., Viale, A., et al. (2015) · Nature · doi:10.1038/nature13828 · Cited by 1,872
Epidemiology and risk factors for IBD
Ananthakrishnan, A. N. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.34 · Cited by 1,741 · cited 2×
“IBD is a common disorder of which the incidence continues to rise, and is attributed to the transition to a sedentary, high fat, high calorie ‘Western lifestyle’.(30)”
BackgroundMicrobiota-mediated colonization resistance against intestinal pathogens
Buffie, C. G., & Pamer, E. G. (2013) · Nature reviews. Immunology · doi:10.1038/nri3535 · Cited by 1,564 · cited 2×
“2).(14,15,18-24) The US Food and Drug Administration (USFDA) already aims to limit the use of antibiotics to reduce the number ofClostridium difficile infections in the USA.”
BackgroundClostridium difficile infection: new developments in epidemiology and pathogenesis
Rupnik, M., Wilcox, M. H., & Gerding, D. N. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2164 · Cited by 1,380 · cited 2×
“Awell-known example of reduced enteric infection resistance through alteration of the gut microbiota caused by medication is the increased risk of Clostridium difficile infections after (repeated) treatment with antibiotics.(16) Antibiotics kill off a large proportion of the gut microbiota, creating an empty niche tha…”
BackgroundProton pump inhibitors affect the gut microbiome
Imhann, F., Bonder, M. J., Vich Vila, A., Fu, J., Mujagic, Z., Vork, L., Tigchelaar, E. F., Jankipersadsing, S. A., Cenit, M. C., Harmsen, H. J. M., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310376 · Cited by 1,371 · cited 5×
“Since the gut microbiota can, depending on composition, increase or decrease the risk of enteric infections, we investigated the effect of PPI use on the gut microbiota.(6)”
BackgroundResultInfluentialSelf-citationHow informative is the mouse for human gut microbiota research?
Nguyen, T. L. A., Vieira-Silva, S., Liston, A., & Raes, J. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.017400 · Cited by 1,334 · cited 1×
“In addition to intervention studies in humans, mouse experiments are required in which gut microbiota changes can be studied in isolation and the effects in tissues and blood markers observed.(39) The effects on enteric-infection-resistance to Clostridium difficile through gut microbiota alterations have already been…”
BackgroundDecreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/525047 · Cited by 1,010
Proton pump inhibitors alter the composition of the gut microbiota
Jackson, M. A., Goodrich, J. K., Maxan, M.-E., Freedberg, D. E., Abrams, J. A., Poole, A. C., Sutter, J. L., Welter, D., Ley, R. E., Bell, J. T., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310861 · Cited by 895
Imhann, F., Vich Vila, A., Bonder, M. J., Fu, J., Gevers, D., Visschedijk, M. C., Spekhorst, L. M., Alberts, R., Franke, L., van Dullemen, H. M., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-312135 · Cited by 788 · cited 1×
“profoundly disturbed balance between favorable and unfavorable gut microbiota, resulting in gut inflammation, is seen in Inflammatory Bowel Disease (IBD).(29)”
BackgroundSelf-citationThe Gut Microbiome Contributes to a Substantial Proportion of the Variation in Blood Lipids
Fu, J., Bonder, M. J., Cenit, M. C., Tigchelaar, E. F., Maatman, A., Dekens, J. A. M., Brandsma, E., Marczynska, J., Imhann, F., Weersma, R. K., et al. (2015) · Circulation Research · doi:10.1161/circresaha.115.306807 · Cited by 748
Self-citationSystematic review of the risk of enteric infection in patients taking acid suppression
Leonard, J., Marshall, J. K., & Moayyedi, P. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01275.x · Cited by 633 · cited 1×
“PPI are also associated with an increased risk of other enteric infections caused by Salmonella, Shigella and Campylobacter species.(4) In the Netherlands, recent trends toward increased incidence of campylobacter infections closely follow trends in the number of PPI prescriptions: both increased rapidly from 2004 to…”
BackgroundAntharam, V. C., Li, E. C., Ishmael, A., Sharma, A., Mai, V., Rand, K. H., & Wang, G. P. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.00845-13 · Cited by 485
Schaubeck, M., Clavel, T., Calasan, J., Lagkouvardos, I., Haange, S. B., Jehmlich, N., Basic, M., Dupont, A., Hornef, M., Bergen, M. V., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-309333 · Cited by 447 · cited 1×
“The effects on gut epithelial inflammation and inflammatory markers can also be studied using IBD mouse models.(40) Finally, mouse experiments can be used to investigate the metabolic effects of gut microbiota alterations.”
BackgroundFreedberg, D. E., Toussaint, N. C., Chen, S. P., Ratner, A. J., Whittier, S., Wang, T. C., Wang, H. H., & Abrams, J. A. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.06.043 · Cited by 322 · cited 3×
“A small intervention study was published a fewmonths before ours and a similar observational study was published in the same issue of Gut.7,8 In Table 1, the bacterial alterations associated with PPI use from all 3 studies are presented at the family level.”
BackgroundResultMcDonald, E. G., Milligan, J., Frenette, C., & Lee, T. C. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.42 · Cited by 216
An Electronic Health Records Study of Long-Term Weight Gain Following Antidepressant Use
Blumenthal, S. R., Castro, V. M., Clements, C. C., Rosenfield, H. R., Murphy, S. N., Fava, M., Weilburg, J. B., Erb, J. L., Churchill, S. E., Kohane, I. S., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.414 · Cited by 151 · cited 2×
“BMI and lipid metabolism Gut microbiota alterations have large effects on body mass index (BMI), lipid- and cholesterol-levels.12,33,34 The effects of some medications on the development of obesity have received considerable attention, for example, the effect of antibiotic use during childhood on obesity 35 Use of oth…”
Background
Cited by
Interaction between drugs and the gut microbiome
Weersma, R. K., Zhernakova, A., & Fu, J. (2020) · Gut · doi:10.1136/gutjnl-2019-320204 · Cited by 961
Self-citationImpact of commonly used drugs on the composition and metabolic function of the gut microbiota
Vich Vila, A., Collij, V., Sanna, S., Sinha, T., Imhann, F., Bourgonje, A. R., Mujagic, Z., Jonkers, D. M. A. E., Masclee, A. A. M., Fu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14177-z · Cited by 791
Self-citationMicrobial regulation of organismal energy homeostasis
Cani, P. D., Van Hul, M., Lefort, C., Depommier, C., Rastelli, M., & Everard, A. (2019) · Nature Metabolism · doi:10.1038/s42255-018-0017-4 · Cited by 569
Gut Microbiota and Colonization Resistance against Bacterial Enteric Infection
Ducarmon, Q. R., Zwittink, R. D., Hornung, B. V. H., van Schaik, W., Young, V. B., & Kuijper, E. J. (2019) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00007-19 · Cited by 566
Blautia genus associated with visceral fat accumulation in adults 20–76 years of age
Ozato, N., Saito, S., Yamaguchi, T., Katashima, M., Tokuda, I., Sawada, K., Katsuragi, Y., Kakuta, M., Imoto, S., Ihara, K., et al. (2019) · npj Biofilms and Microbiomes · doi:10.1038/s41522-019-0101-x · Cited by 416
Metadata
- Authors
- Imhann, F., Vich Vila, A., Bonder, M. J., Lopez Manosalva, A. G., Koonen, D. P. Y., Fu, J., Wijmenga, C., Zhernakova, A., & Weersma, R. K.
- Venue
- Gut Microbes
- Publisher
- Informa UK Limited
- Published
- 2017-01-24
- Volume
- 8
- Issue
- 4
- Pages
- 351-358
- ISSN
- 1949-0976 (ISSN-L)
- 1949-0984
- OpenAlex
- W2582320162
- Cited by
- 192
- References
- 23
- FWCI
- 6.41
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.